Complement component C5 is the target of the monoclonal antibody Eculizumab, and the focus of a sustained drug discovery effort to prevent complement-induced inflammation in a range of autoimmune diseases. The immune evasion protein OmCI binds to, and potently inactivates, C5; this tight-binding interaction can be exploited to affinity-purify C5 protein from serum, offering a vastly simplified protocol compared to existing methods. However, breaking the high-affinity interaction requires conditions which risk denaturing or activating C5. We performed structure-guided in silico mutagenesis to identify prospective OmCI residues that contribute significantly to the binding affinity. We tested our predictions in vitro, using site directed mutagenesis, and characterised mutants using a range of biophysical techniques as well as functional assays. Our biophysical analyses suggest the C5-OmCI interaction is complex with potential for multiple binding modes.We present single mutations that lower the affinity of OmCI for C5 and combinations of mutations that significantly decrease, or entirely abrogate, formation of the complex. The affinity attenuated forms of OmCI are suitable for affinity purification and allow elution under mild conditions that are non-denaturing or activating to C5. We present the rational design, biophysical characterisation and experimental validation of affinity reduced forms of OmCI as tool reagents to enable the affinity purification of C5.
ASJC Scopus subject areas
- Molecular Biology
- Cell Biology
FingerprintDive into the research topics of 'The rational design of affinity attenuated OmCI for the purification of Complement C5'. Together they form a unique fingerprint.
- Department of Life Sciences - Professor
- Centre for Sustainable and Circular Technologies (CSCT)
- Centre for Therapeutic Innovation
- Centre for Biosensors, Bioelectronics and Biodevices (C3Bio)
- Centre for Integrated Bioprocessing Research (CIBR)
- Milner Centre for Evolution
Person: Research & Teaching